(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Mechanisms investigated BPC-157 and TB-500 are structurally unrelated peptides studied through different pathways, which is the rationale for both the standalone reagents and the co-formulated blends: BPC-157 (gastric pentadecapeptide): a synthetic 15-amino-acid peptide derived from a protective protein in gastric juice, studied for cytoprotection, angiogenesis and epithelial healing in vitro and in animal models
Why the 72-hour rule exists Numbers without context are just numbers
A 10mg vial at 2.5 mg per week lasts 4 weeks
mRNAs were encapsulated in LNPs
Some people may experience: Mild discomfort or redness at the injection site Nausea Mild reactions such as headache or dizziness Serious reactions are rare
